ATE290391T1 - Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen - Google Patents

Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen

Info

Publication number
ATE290391T1
ATE290391T1 AT99957817T AT99957817T ATE290391T1 AT E290391 T1 ATE290391 T1 AT E290391T1 AT 99957817 T AT99957817 T AT 99957817T AT 99957817 T AT99957817 T AT 99957817T AT E290391 T1 ATE290391 T1 AT E290391T1
Authority
AT
Austria
Prior art keywords
lactobacillus
oral administration
prevention
treatment
urogenital infections
Prior art date
Application number
AT99957817T
Other languages
English (en)
Inventor
Gregor Reid
Andrew W Bruce
Original Assignee
Urex Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urex Biotech Inc filed Critical Urex Biotech Inc
Application granted granted Critical
Publication of ATE290391T1 publication Critical patent/ATE290391T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99957817T 1998-12-11 1999-12-10 Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen ATE290391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11196598P 1998-12-11 1998-12-11
PCT/CA1999/001182 WO2000035465A2 (en) 1998-12-11 1999-12-10 Oral administration of lactobacillus for the treatment and prevention of urogenital infection

Publications (1)

Publication Number Publication Date
ATE290391T1 true ATE290391T1 (de) 2005-03-15

Family

ID=22341404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957817T ATE290391T1 (de) 1998-12-11 1999-12-10 Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen

Country Status (15)

Country Link
US (1) US6479051B1 (de)
EP (1) EP1137423B1 (de)
JP (1) JP2003522731A (de)
KR (1) KR20010101171A (de)
AT (1) ATE290391T1 (de)
AU (1) AU1543400A (de)
BR (1) BR9916062A (de)
CA (1) CA2354054C (de)
DE (1) DE69924141D1 (de)
ID (1) ID30071A (de)
IL (1) IL143632A0 (de)
NZ (1) NZ512275A (de)
PL (1) PL348973A1 (de)
TR (1) TR200101699T2 (de)
WO (1) WO2000035465A2 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374937A1 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
DE60137235D1 (de) * 2000-08-25 2009-02-12 Wakamoto Pharma Co Ltd L. salivarius-Stamm enthaltende probiotische Produkte
SE521022C2 (sv) * 2001-09-20 2003-09-23 Ellen Ab Mjölksyraproducerande bakterier för användning som probiotiska organismer i vaginan hos människa
JP4510376B2 (ja) 2000-10-06 2010-07-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 皮膚の免疫系のバランスを保つためのプロバイオティック乳酸菌の使用
IL156490A0 (en) * 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
CA2436264C (en) * 2001-02-06 2014-01-28 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
EE04580B1 (et) * 2001-06-29 2006-02-15 Tartu �likool Mikroorganismi tüvi Lactobacillus fermentum ME-3 kui antimikroobne ja antioksüdantne probiootikum
JP4402952B2 (ja) * 2001-07-23 2010-01-20 ザ・アイムス・カンパニー 食品用表面コーティング組成物のライン上での混合及び適用のためのシステム及び方法
CN100478026C (zh) * 2001-09-28 2009-04-15 纽特休迪克斯公司 用于生物学组分的传递系统
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
US7829079B2 (en) * 2002-03-28 2010-11-09 Christian Hansen A/S Lactobacillus iners for the enhancement of urogenital health
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
CA2512812A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
GB0410785D0 (en) * 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060062742A1 (en) * 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for reduction of human malodor
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
WO2006045474A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same
WO2006045347A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
BRPI0610609A2 (pt) * 2005-04-15 2010-07-06 Univ North Carolina State métodos e composições para modular a adesão e toleráncia ao estresse em bactérias
US20070082035A1 (en) 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
US20110064706A1 (en) * 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
PL2349295T3 (pl) * 2008-11-17 2017-06-30 Winclove Holding B.V. Preparat farmaceutyczny zawierający kombinację szczepów paciorkowców i szczepów lactobacillus
EP2206506A1 (de) * 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotische Formulierungen
KR101690090B1 (ko) 2009-07-16 2016-12-27 고쿠리츠다이가쿠호진 히로시마다이가쿠 구강내 질환의 예방, 개선 또는 치료제
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
MX348611B (es) * 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
NZ607043A (en) 2010-08-04 2015-05-29 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP2428214A1 (de) 2010-09-14 2012-03-14 HSO Health Care GmbH Zusammensetzungen für die vaginale und orale Verabreichung des Lactobacillus und Verwendungen davon
EE05721B1 (et) * 2011-02-25 2014-08-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tüvi L. plantarum MCC1 DSM 23881 ja selle kasutamine
WO2012118535A1 (en) 2011-03-01 2012-09-07 Quorum Innovations, Llc Materials and methods for treating conditions associated with pathogenic biofilm
US20120230957A1 (en) * 2011-03-09 2012-09-13 Northwestern University Compositions and methods for treatment of pain
CA2829385C (en) 2011-03-09 2021-07-13 Michael J. Sadowsky Compositions and methods for transplantation of colon microbiota
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
KR101287126B1 (ko) * 2011-10-28 2013-07-17 대상에프앤에프 주식회사 식물성유산균발효액을 함유하는 질염 및 요로감염 예방 및 치료용 약학 조성물
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
CA2869566C (en) 2012-04-05 2022-08-30 London Health Sciences Centre Research Inc. Food grade bacteria for the removal of toxic compounds
FR2992861B1 (fr) 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
FR2992973B1 (fr) 2012-07-09 2015-12-18 S P M D Nouvelle souche de lactobacillus crispatus
WO2014122175A1 (en) * 2013-02-07 2014-08-14 Lonza Ltd. Composition comprising lactobacillus and a carrier
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
EP4529950A3 (de) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung von störungen
EP3064072A1 (de) * 2015-02-11 2016-09-07 AB-Biotics S.A. Probiotische Lactobacillus Stämme und ihre Verwendung zur Behandlung von Harnwegsinfektionen
BR112017023059B1 (pt) 2015-04-28 2022-07-05 Mars, Incorporated Processo para preparar um produto de ração úmida esterilizada, produto de ração úmida esterilizada, e seu uso
JP6990922B2 (ja) 2015-05-11 2022-01-12 マイバイオティクス ファーマ リミテッド 腸における細菌のコロニー形成のために固体粒子上で生菌のバイオフィルムを成長させるためのシステムおよび方法
PT3297644T (pt) 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
US10588926B2 (en) * 2015-06-29 2020-03-17 Ferring B.V. Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis
FR3048361B1 (fr) 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
IL263218B (en) 2016-05-25 2022-07-01 Mybiotics Pharma Ltd Composition and methods for microbiota therapy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
EP3512532A1 (de) 2016-09-16 2019-07-24 DuPont Nutrition Biosciences ApS Bakterien
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
EP3606541A1 (de) 2017-04-05 2020-02-12 Crestovo Holdings LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit (pd) und verwandten erkrankungen
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3064773A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CN111328284A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于维持和恢复健康的肠道屏障的组合物和方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
AU2020316330A1 (en) 2019-07-19 2022-01-06 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
US20210268046A1 (en) * 2020-02-18 2021-09-02 HoneyHills TX, LLC Cannabinoid & probiotic suppositories & methods of use
IT202000016666A1 (it) * 2020-07-09 2022-01-09 Uriach Italy S R L Nuovo ceppo della specie lacticaseibacillus rhamnosus, sue composizioni e loro uso nel trattamento di infezioni genitourinarie
CN116096856A (zh) 2020-08-28 2023-05-09 科·汉森有限公司 利用辛烯基琥珀酸酐淀粉-壳聚糖复合团聚体微囊化微生物培养物
US12318417B2 (en) 2020-12-23 2025-06-03 Church & Dwight Co., Inc. Lactobacillus compositions and methods for prevention and treatment of microbial infection
CN112708583B (zh) * 2021-01-29 2022-05-17 重庆第二师范学院 一种发酵乳杆菌lf-schy34及其应用
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물
WO2024184258A1 (en) 2023-03-03 2024-09-12 Chr. Hansen A/S Compositions comprising lactobacillus reuteri, lactobacillus rhamnosus, and 2'-fucosyllactose
WO2025202427A1 (en) 2024-03-28 2025-10-02 Chr. Hansen A/S Microencapsulated microbial culture using protein-carbohydrate and chitosan complex coacervate polymer
CN118360221B (zh) * 2024-06-19 2024-09-13 南昌大学 一株卷曲乳杆菌ncu-23及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6051552A (en) * 1996-05-30 2000-04-18 Urex Biotech, Inc. Lactobacillus therapies
ES2283027T3 (es) 1996-11-29 2007-10-16 Bio K + International Inc. Fermento lactico que comprende una cepa particular de lactobacilus acidofilus y utilizacion del mismo.

Also Published As

Publication number Publication date
IL143632A0 (en) 2002-04-21
EP1137423A2 (de) 2001-10-04
BR9916062A (pt) 2002-09-24
DE69924141D1 (de) 2005-04-14
JP2003522731A (ja) 2003-07-29
NZ512275A (en) 2003-11-28
TR200101699T2 (tr) 2002-06-21
PL348973A1 (en) 2002-06-17
WO2000035465A3 (en) 2000-12-28
KR20010101171A (ko) 2001-11-14
CA2354054C (en) 2011-04-12
WO2000035465A2 (en) 2000-06-22
ID30071A (id) 2001-11-01
US6479051B1 (en) 2002-11-12
EP1137423B1 (de) 2005-03-09
CA2354054A1 (en) 2000-06-22
AU1543400A (en) 2000-07-03

Similar Documents

Publication Publication Date Title
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
BR0116349A (pt) Compostos probióticos derivados da cepa ke01 de lactobacillus casei
ATE407687T1 (de) Probiotisches milchsäurebakterium zur behandlung bakterieller infektionen in zusammenhang mit sids
HUT75555A (en) Lactobacillus strains of human origin, their compositions and uses thereof
DE69802260D1 (de) Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
WO2000071138A3 (en) Oral administration of lactobacillus for the maintenance of health in women
HK1049115A1 (zh) 治療過敏性失調的成分和方法
DE60139554D1 (de) Probiotika zur primären prävention atopischer erkrankungen
DE60205646D1 (de) Einen lactobacillus-stamm enthaltende zusammensetzung und verwendungen davon
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
BR0008920A (pt) Cepas de lactobacillus capazes de prevenirdiarréia causada por bactéria patogênica erotaviroses
DE60214029D1 (de) Milchsäurebakterien und deren verwendungen zur behandlung von und vorbeugung gegen krebs
WO2003039260A3 (en) PROBIOTIC COMPOSITIONS
CA2314775A1 (en) Novel lactic acid bacterial preparation that reduces triglycerides and cholesterol
BR0012973B1 (pt) Uso de bactéria do ácido láctico pertencente ao gênero Bifidobacterium, e composição alimentícia ou farmacêutica.
ATE307575T1 (de) Zusammensetzung geeignet als nahrungsmittelzusatz und zur anwendung bei darmerkrankungen sowie bei veränderter darmflora
NO20014788D0 (no) En sammensetning for senkning av konsentrasjonen av sykdomsfremkallende tarmpeptider
DE60012521D1 (de) BAKTERIENSTAMM LACTOBACILLUS ACIDOPHILUS N.V. EP 317/402 NARINE, WELCHER ZUR HERSTELLUNG VON ZUSAMMENSETZUNGEN UND VON DIäTETISCHEN, THERAPEUTISCHEN UND PROPHYLAKTISCHEN PRODUKTEN ZUR BEHANDLUNG VON DYSBAKTERIOSE UND DEREN FOLGEN VERWENDET WIRD
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE443755T1 (de) Erkennung, vorbeugung und behandlung papillomatöser digitaler dermatitis
MD1305B2 (en) Nutrient medium for selective separation of the Enterobacteriaceae family representatives
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.
SE9902673D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties